Mechanisms of Myeloid Leukemogenesis: Current Perspectives and Therapeutic Objectives

Overview

Journal Blood Rev

Publisher Elsevier

Specialty Hematology

Date 2022 Aug 21

PMID 35989139

Authors

Ian M Bouligny

Keri R Maher

Steven Grant

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm which results in clonal proliferation of abnormally differentiated hematopoietic cells. In this review, mechanisms contributing to myeloid leukemogenesis are summarized, highlighting aberrations of epigenetics, transcription factors, signal transduction, cell cycling, and the bone marrow microenvironment. The mechanisms contributing to AML are detailed to spotlight recent findings that convey clinical impact. The applications of current and prospective therapeutic targets are accentuated in addition to reviews of treatment paradigms stratified for each characteristic molecular lesion - with a focus on exploring novel treatment approaches and combinations to improve outcomes in AML.

Citing Articles

Editorial for the Special Issue 'Molecular Mechanisms of Leukemia'.

An J, Ko M Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852129 PMC: 11763483. DOI: 10.3390/cimb47010014.

A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.

Maher K, Shafer D, Schaar D, Bandyopadhyay D, Deng X, Wright J Cancer Chemother Pharmacol. 2025; 95(1):24.

PMID: 39821392 PMC: 11742280. DOI: 10.1007/s00280-024-04742-9.

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.

Koolivand Z, Bahreini F, Rayzan E, Rezaei N Heliyon. 2025; 11(1):e41355.

PMID: 39811307 PMC: 11730532. DOI: 10.1016/j.heliyon.2024.e41355.

Single-cell transcriptome profiling of mA regulator-mediated methylation modification patterns in elderly acute myeloid leukemia patients.

Wang Z, Du X, Zhang P, Zhao M, Zhang T, Liu J Mol Biomed. 2024; 5(1):66.

PMID: 39641872 PMC: 11624184. DOI: 10.1186/s43556-024-00234-7.

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.

Shaffer B, Kebriaei P, de Lima M, Jimenez Jimenez A Bone Marrow Transplant. 2024; 60(2):128-134.

PMID: 39562717 PMC: 11810777. DOI: 10.1038/s41409-024-02481-2.

References

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

Wang S, Speck N . Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Mol Cell Biol. 1992; 12(1):89-102. PMC: 364072. DOI: 10.1128/mcb.12.1.89-102.1992. View

Look A, Kirstein M, Valentine M, Raimondi S, Cohen K, Carroll A . The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 1996; 12(2):265-75. View

Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

Pan T, Qi J, You T, Yang L, Wu D, Han Y . Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort.... Leuk Res. 2018; 71:13-24. DOI: 10.1016/j.leukres.2018.06.007. View

Brunetti L, Gundry M, Sorcini D, Guzman A, Huang Y, Ramabadran R . Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018; 34(3):499-512.e9. PMC: 6159911. DOI: 10.1016/j.ccell.2018.08.005. View

Alberich-Jorda M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A . C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. J Clin Invest. 2012; 122(12):4490-504. PMC: 3533560. DOI: 10.1172/JCI65102. View

Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C . Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016; 107(10):1422-1429. PMC: 5084664. DOI: 10.1111/cas.13019. View

Hamdi W, Ogawara H, Handa H, Tsukamoto N, Nojima Y, Murakami H . Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. Eur J Haematol. 2008; 82(3):201-7. DOI: 10.1111/j.1600-0609.2008.01182.x. View

10.

Jasielec J, Saloura V, Godley L . The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 2014; 28(9):1765-73. DOI: 10.1038/leu.2014.163. View

11.

Guenther M, Lawton L, Rozovskaia T, Frampton G, Levine S, L Volkert T . Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2009; 22(24):3403-8. PMC: 2607073. DOI: 10.1101/gad.1741408. View

12.

Pollard J, Alonzo T, Gerbing R, Ho P, Zeng R, Ravindranath Y . Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010; 115(12):2372-9. PMC: 2845895. DOI: 10.1182/blood-2009-09-241075. View

13.

Seshadri M, Qu C . Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis. Curr Opin Hematol. 2016; 23(4):339-45. PMC: 5086033. DOI: 10.1097/MOH.0000000000000251. View

14.

Borthakur G, Kantarjian H . Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021; 11(6):114. PMC: 8209225. DOI: 10.1038/s41408-021-00503-6. View

15.

Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C . Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009; 114(8):1628-32. DOI: 10.1182/blood-2009-01-197525. View

16.

Zhao D, Tahaney W, Mazumdar A, Savage M, Brown P . Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci. 2017; 74(22):4171-4187. PMC: 5664959. DOI: 10.1007/s00018-017-2575-0. View

17.

Brinton L, Sher S, Williams K, Canfield D, Orwick S, Wasmuth R . Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers (Basel). 2020; 12(6). PMC: 7352446. DOI: 10.3390/cancers12061574. View

18.

Peterson L, Zhang D . The 8;21 translocation in leukemogenesis. Oncogene. 2004; 23(24):4255-62. DOI: 10.1038/sj.onc.1207727. View

19.

Yi L, Sun Y, Levine A . Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget. 2014; 5(19):8924-36. PMC: 4253407. DOI: 10.18632/oncotarget.2441. View

20.

Carter J, Hege K, Yang J, Kalpage H, Su Y, Edwards H . Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020; 5(1):288. PMC: 7746731. DOI: 10.1038/s41392-020-00361-x. View